Ability Pharma
AbilityPharma is a clinical stage phase 2b biopharmaceutical company focused on autophagy to treat cancer. Learn more
Launch date
Employees
Market cap
-
Enterprise valuation
AUD47m (Public information from Mar 2024)
Cerdanyola del Vallès Catalonia (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
€1.0m | Early VC | ||
* | €1.2m | Seed | |
* | €3.5m | Early VC | |
€2.3m | Grant | ||
€1.6m | Grant | ||
€2.0m | Seed | ||
€850k | Early VC | ||
* | €7.0m Valuation: €27.7m | Early VC | |
Total Funding | AUD33.2m |
Related Content
Recent News about Ability Pharma
EditMore about Ability Pharma
EditDeveloper of medical therapies intended to focus on developing fully differentiated oral targeted anticancer compounds. The company's targeted therapies are drugs that kill cancer cells through the induction of robust cytotoxic autophagy, enabling doctors to improve the lives of the patients and cure them.
Keywords: Pharmaceuticals and Biotechnology, Biopharmaceutical Company, Cancer Care, Cancer Drug Discovery, Cell Membrane, Gynecological Cancer, Healthcare Services, Therapeutic Strategy.
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.